T1	Participants 50 114	older adolescents and young adults with autism spectrum disorder
T2	Participants 294 372	Older adolescents and young adults are particularly impacted by these deficits
T3	Participants 905 1246	Males and females, ages 14 to 25 years, with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of an ASD were enrolled in a double-blind, randomized 10-week trial consisting of 8 weeks of active drug with either weekly or daily administration of 50 mg of DCS followed by a 2-week follow-up visit
T4	Participants 1288 1459	no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3, which measures stereotypies/repetitive movements.
T5	Participants 1460 1638	When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003).
T6	Participants 1651 1827	D-Cycloserine was shown to be effective in improving stereotypic symptoms in older adolescents and young adults with ASDs measured by the Aberrant Behavior Checklist subscale 3
T7	Participants 1842 1873	DCS was safe and well tolerated
